ClinicalTrials.gg

Program

CCR8 Inhibitor IPG7236

Also written as “IPG7236”, “IPG7236- Single ascending dose” and “IPG7236- Multiple ascending dose”.

Its studies are mostly in Dermatitis, Atopic, led by Nanjing Immunophage Biotech.

Furthest: phase 2, since Nov 21, 20213 company-led studies, 1 open or runningNext primary completion: Dec 30, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Nanjing Immunophage Biotech31 open or runningphase 2since Nov 21, 2021Nov 21, 2021Dec 30, 2028phase 2 · NCT07508761

Also a collaborator on its studies: Novotech (Australia) Pty.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 21, 2021First study: phase 2 study in Safety IssuesFirst studyNCT05142592 · 34 enrolled · United States, China
  2. Mar 17, 2022Phase 1 study in Dermatitis, AtopicNCT05288543 · 63 enrolled · Australia
  3. Mar 23, 2026Phase 2 study in Advanced Solid TumorNCT07508761 · 52 planned · China

Ahead

  1. Dec 30, 2028Primary completion: phase 2 study in Advanced Solid TumorNCT07508761

TargetBeta

CCR8 →read by rule
“An orally bioavailable inhibitor of C-C-chemokine receptor 8 (CCR8), ”NCIt, by rule

Other programs on CCR8

ProgramCompanyFurthest phaseStudies
cafelkibartSino Biopharmaceuticalphase 37
denikitugruleGilead Sciencesphase 23
imzokitugBristol-Myers Squibbphase 22
Anti-CCR8 Antibody-drug Conjugate TAK-188ruleTakedaphase 21
Anti-CCR8 Monoclonal Antibody HC006rulehc-biopharma-incphase 12
azirkitugAbbViephase 11

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07508761Advanced Solid Tumor · China2RecruitingDec 30, 202852
NCT05288543Dermatitis, Atopic · Australia1TerminatedMar 31, 202363
NCT05142592Safety Issues · United States, China2CompletedFeb 8, 202634

How it is read

Names in the registry

  • “IPG7236”, 2 entries
  • “IPG7236- Single ascending dose”, 1 entry
  • “IPG7236- Multiple ascending dose”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.